All the Active Ingredient Drugs
(ADP-ribose) polymerase (PARP) inhibitor. Talazoparib Tosylate 0.25 mg, 1 mg. HARD CAPS.: 30×1 mg, 60×0.25 mg. 1 mg ×1/d taken orally, with/without food.
The 0.25 mg cap. is available for dose reduction.
Pts. should be treated until dis. progres. or unaccept. toxicity occurs.
To avoid contact with the caps. content, Talazoparib cap. should be swallow. whole, and must not be opened or dissolve.
If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time.
Dose reduct. levels for adverse react. -See lit.
Tmt. of adult pts. with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epiderm. growth factor receptor 2 (HER2)-negative locally advanc. or metastat. breast cancer.